The Biomarkers Of RIsk of Colorectal Cancer (BORICC) Follow-Up (BFU) Study
- Conditions
- Colorectal Cancer
- Registration Number
- NCT04005742
- Lead Sponsor
- Newcastle University
- Brief Summary
Worldwide, colorectal cancer is the 3rd most common cancer; risk increases with age and is modified by lifestyle factors notably diet, physical activity and obesity. The BORICC Follow-Up (BFU) Study is a 12+ year follow-up of participants recruited to the Biomarkers of Risk of Colon Cancer (BORICC) Study. This longitudinal study will investigate associations between ageing and lifestyle factors and a panel of molecular biomarkers linked with colorectal cancer risk.
- Detailed Description
The BORICC Follow-Up (BFU) Study builds on the findings from the BORICC Study where the investigators observed associations between age and nutritional factors, including selenium and folate, and biomarkers of colorectal health.
The BFU Study will investigate the relationships between ageing (12+ years) and such biomarkers longitudinally. It is anticipated that the project will produce novel data on (i) changes in biomarkers of colorectal cancer risk with age and (ii) the effects of obesity and lifestyle factors on biomarkers of colorectal cancer risk. These biomarkers include differentially expressed proteins, DNA methylation markers and inflammation markers.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 47
- Took part in the BORICC Study at baseline (recruited 2005/6)
- Unable to travel to the hospital to attend study visit
- Unable to provide informed written consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Faecal calprotectin concentrations (marker of local inflammation) 12 years (on average) Serum high-sensitivity C-Reactive Protein concentrations (marker of systemic inflammation) 12 years (on average)
- Secondary Outcome Measures
Name Time Method Faecal short-chain fatty acid concentrations 12 years (on average) Concentrations and proportions of short-chain fatty acids e.g. acetate, propionate and butyrate
DNA methylation in rectal mucosal biopsies(% methylation) 12 years (on average) Target gene and global methylation (LINE-1) in rectal mucosal biopsies
Colonic crypt cell dimensions 12 years (on average) Height (length) and width rectal mucosal crypts
Parathyroid hormone in plasma 12 years (on average) Triglycerides in plasma 12 years (on average) Vitamin B12 concentrations in serum 12 years (on average) Folate concentrations in serum 12 years (on average) HDL cholesterol in plasma 12 years (on average) Gut microbiota (analysed in stool samples) 12 years (on average) Abundance and diversity of the gut microbiota assessed in stool samples
Target gene expression in rectal mucosal biopsies 12 years (on average) Expression of genes related to inflammation and the WNT signalling pathway in rectal mucosal biopsies
microRNA expression in rectal mucosal biopsies 12 years (on average) Expression of microRNAs in rectal mucosal biopsies
Colonic crypt cell proliferative state 12 years (on average) Total number and distribution of proliferating cells in rectal mucosal crypts
Markers of mitochondrial function and structure in rectal mucosal biopsies 12 years (on average) Markers of mitochondrial function and structure in rectal mucosal biopsies such as oxidative phosphorylation proteins, namely complex I and IV
25-hydroxy vitamin D concentrations in serum 12 years (on average) LDL cholesterol in plasma 12 years (on average) Glucose in plasma 12 years (on average) HbA1c in whole blood 12 years (on average) Total cholesterol in plasma 12 years (on average)
Trial Locations
- Locations (1)
North Tyneside General Hospital
🇬🇧North Shields, Tyne & Wear, United Kingdom